This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
This week’s new post on the CLL Society website is an update of the data from trials with ibrutinib in treatment-naïve and relapsed patients presented by Dr. Byrd from an interview done at the CRC (CLL Research Consortium) meeting in San Diego in April 2015.
Dr. Byrd presents the long-term data from patients having received almost three years of treatment with ibrutinib for chronic lymphocytic leukemia. The data are increasingly positive, however there are still concerns with relapse, especially in those with genetic instability such as those with 17p deletion or a complex karyotype.
Still the news is good.
We are all in this together.
Volunteer Medical Director of the CLL Society